Advertisement

Topics

IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results

04:05 EDT 12 Sep 2017 | Pharmaceutical Business Review

IRX Therapeutics has presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society for Medical Oncology (ESMO) Annual Congress 2017.

Original Article: IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results

NEXT ARTICLE

More From BioPortfolio on "IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...